Physician profile
Pamela Quinlan
NPI 1619959913
$833.33
in general payments reported to CMS, 2019-2025
11 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.83 · 2020: $430 · 2021: $57.55 · 2022: $98.82 · 2023: $57.56 · 2024: $18.52 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $419.21 | 2019-2020 | |
| Medtronic, INC. | $82.30 | 2025 | Minimed 780g |
| Lifescan, INC. | $81.30 | 2020-2021 | |
| Lilly USA, LLC | $68.31 | 2023-2025 | Jardiance, Mounjaro, Trulicity |
| Dexcom, INC. | $40.76 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $33.12 | 2021-2022 | |
| Abbvie INC. | $30.57 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $24.59 | 2022 | |
| Ibsa Pharma INC. | $21.62 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.57 | 2022 | |
| Novo Nordisk INC | $12.98 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Quinlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.